Immunohematology

Immune cytopenias and screening blood donors for immune response to infection

T. H. Price, M. H. Sayers, B. C. Gilliland

Research output: Contribution to journalArticle

Abstract

One of the most remarkable aspects of screening blood donors for evidence of their immune response to infectious agents is the size and scope of the undertaking. Some 3 million patients a year in America require transfusions, which are provided by about 13 million donations. Against this background, screening in the interests of ensuring transfusion safety for patients also represents a massive public health intervention from the standpoint of notifying and counseling donors about positive test results. For some markers, particularly HBsAg, anti-HIV, and anti-HCV, this is vitally important information. The chronic carrier of hepatitis B can be warned about possible health outcomes and close contacts can be offered vaccination. Many donors found to be truly positive for HIV antibodies were infected unwittingly and otherwise might not have been made aware of their infection. It is possible that similar benefits will accrue in the notification of donors found to be truly positive for antibodies to HCV. Many of these donors also were infected unwittingly. As better understanding of the value of treatment for the HCV-infected patient emerges, particularly with the use of interferon, early treatment of asymptomatic individuals may enable them to escape long-term complications of HCV infection. Although some progress is being made toward the viral inactivation of products for transfusion, particularly clotting factor concentrates, it is highly likely that the mainstay of transfusion safety will continue to be screening donors for markers of infectious disease. As was pointed out earlier, careful consideration must be given to the usefulness of additional donor screening. This is particularly true for rarely transmitted infectious diseases in which screening will result in further attrition of the donor base as a result of nonspecific test results.

Original languageEnglish (US)
Pages (from-to)425-449
Number of pages25
JournalImmunology and Allergy Clinics of North America
Volume14
Issue number2
StatePublished - 1994

Fingerprint

Blood Donors
Tissue Donors
Donor Selection
Infection
Communicable Diseases
Virus Inactivation
HIV Antibodies
Hepatitis C Antibodies
Blood Coagulation Factors
Chronic Hepatitis B
Patient Safety
Hepatitis B Surface Antigens
Interferons
Counseling
Vaccination
Public Health
HIV
Safety
Health
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Immunohematology : Immune cytopenias and screening blood donors for immune response to infection. / Price, T. H.; Sayers, M. H.; Gilliland, B. C.

In: Immunology and Allergy Clinics of North America, Vol. 14, No. 2, 1994, p. 425-449.

Research output: Contribution to journalArticle

@article{f625b922fdb544d99907026bc35acfc5,
title = "Immunohematology: Immune cytopenias and screening blood donors for immune response to infection",
abstract = "One of the most remarkable aspects of screening blood donors for evidence of their immune response to infectious agents is the size and scope of the undertaking. Some 3 million patients a year in America require transfusions, which are provided by about 13 million donations. Against this background, screening in the interests of ensuring transfusion safety for patients also represents a massive public health intervention from the standpoint of notifying and counseling donors about positive test results. For some markers, particularly HBsAg, anti-HIV, and anti-HCV, this is vitally important information. The chronic carrier of hepatitis B can be warned about possible health outcomes and close contacts can be offered vaccination. Many donors found to be truly positive for HIV antibodies were infected unwittingly and otherwise might not have been made aware of their infection. It is possible that similar benefits will accrue in the notification of donors found to be truly positive for antibodies to HCV. Many of these donors also were infected unwittingly. As better understanding of the value of treatment for the HCV-infected patient emerges, particularly with the use of interferon, early treatment of asymptomatic individuals may enable them to escape long-term complications of HCV infection. Although some progress is being made toward the viral inactivation of products for transfusion, particularly clotting factor concentrates, it is highly likely that the mainstay of transfusion safety will continue to be screening donors for markers of infectious disease. As was pointed out earlier, careful consideration must be given to the usefulness of additional donor screening. This is particularly true for rarely transmitted infectious diseases in which screening will result in further attrition of the donor base as a result of nonspecific test results.",
author = "Price, {T. H.} and Sayers, {M. H.} and Gilliland, {B. C.}",
year = "1994",
language = "English (US)",
volume = "14",
pages = "425--449",
journal = "Immunology and Allergy Clinics of North America",
issn = "0889-8561",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Immunohematology

T2 - Immune cytopenias and screening blood donors for immune response to infection

AU - Price, T. H.

AU - Sayers, M. H.

AU - Gilliland, B. C.

PY - 1994

Y1 - 1994

N2 - One of the most remarkable aspects of screening blood donors for evidence of their immune response to infectious agents is the size and scope of the undertaking. Some 3 million patients a year in America require transfusions, which are provided by about 13 million donations. Against this background, screening in the interests of ensuring transfusion safety for patients also represents a massive public health intervention from the standpoint of notifying and counseling donors about positive test results. For some markers, particularly HBsAg, anti-HIV, and anti-HCV, this is vitally important information. The chronic carrier of hepatitis B can be warned about possible health outcomes and close contacts can be offered vaccination. Many donors found to be truly positive for HIV antibodies were infected unwittingly and otherwise might not have been made aware of their infection. It is possible that similar benefits will accrue in the notification of donors found to be truly positive for antibodies to HCV. Many of these donors also were infected unwittingly. As better understanding of the value of treatment for the HCV-infected patient emerges, particularly with the use of interferon, early treatment of asymptomatic individuals may enable them to escape long-term complications of HCV infection. Although some progress is being made toward the viral inactivation of products for transfusion, particularly clotting factor concentrates, it is highly likely that the mainstay of transfusion safety will continue to be screening donors for markers of infectious disease. As was pointed out earlier, careful consideration must be given to the usefulness of additional donor screening. This is particularly true for rarely transmitted infectious diseases in which screening will result in further attrition of the donor base as a result of nonspecific test results.

AB - One of the most remarkable aspects of screening blood donors for evidence of their immune response to infectious agents is the size and scope of the undertaking. Some 3 million patients a year in America require transfusions, which are provided by about 13 million donations. Against this background, screening in the interests of ensuring transfusion safety for patients also represents a massive public health intervention from the standpoint of notifying and counseling donors about positive test results. For some markers, particularly HBsAg, anti-HIV, and anti-HCV, this is vitally important information. The chronic carrier of hepatitis B can be warned about possible health outcomes and close contacts can be offered vaccination. Many donors found to be truly positive for HIV antibodies were infected unwittingly and otherwise might not have been made aware of their infection. It is possible that similar benefits will accrue in the notification of donors found to be truly positive for antibodies to HCV. Many of these donors also were infected unwittingly. As better understanding of the value of treatment for the HCV-infected patient emerges, particularly with the use of interferon, early treatment of asymptomatic individuals may enable them to escape long-term complications of HCV infection. Although some progress is being made toward the viral inactivation of products for transfusion, particularly clotting factor concentrates, it is highly likely that the mainstay of transfusion safety will continue to be screening donors for markers of infectious disease. As was pointed out earlier, careful consideration must be given to the usefulness of additional donor screening. This is particularly true for rarely transmitted infectious diseases in which screening will result in further attrition of the donor base as a result of nonspecific test results.

UR - http://www.scopus.com/inward/record.url?scp=0028308201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028308201&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 425

EP - 449

JO - Immunology and Allergy Clinics of North America

JF - Immunology and Allergy Clinics of North America

SN - 0889-8561

IS - 2

ER -